Main description:

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.

Contents:

Challenges in Drug Discovery at Schering-Plough Research Institute: A Personal Reflection
My Perspective on Time, Managers-and Scientific Fun
A Career in Medicinal Chemistry - A Journey in Drug Discovery
Selective Inhibitors of PDE2, PDE9 and PDE10 - Modulators of Activity of the Central Nervous System
Beyond Secretases: Kinases Inhibitors for the Treatment of Alzheimer's Disease
Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders
Discovery and Development of Prolylcarboxypeptidase (PRCP) Inhibitors for Cardiometabolic Disorders
Molecular Targeting of Imaging and Drug Delivery Probes in Atherosclerosis
Oral GLP-1 Modulators for the Treatment of Diabetes
Recent Advances in the Discovery and Development of CCR1 Antagonists
Emerging Targets for the Treatment of Idiopathic Pulmonary Fibrosis
Targeting the Nuclear Hormone Receptor RORgt for the Treatment of Autoimmune and Inflammatory Disorders
Recent Advances in Small-Molecule Modulation of Epigenetic Targets: Discovery and Development of Histone Methyltransferase- and Bromodomain Inhibitors
Inhibition of Ubiquitin Proteasome System Enzymes for Anticancer Therapy
Targeting Protein-Protein Interactions to Treat Cancer?Recent Progress and Future Directions
Recent Progress in the Discovery of Neuraminidase Inhibitors as Anti-influenza Agents
Novel Therapeutics in Discovery and Development for Treatment of Chronic HBV Infection
Special Challenges to the Rational Design of Antibacterial Agents
Recent Advances in Small Molecule Target Identification Methods
Neuroinflammation in Mood Disorders: Mechanisms and Drug Targets
Inhibitors of hERG Channel Trafficking-A Cryptic Mechanism For QT Prolongation
Recent Progress in Small-Molecule Agents Against Age-Related Macular Degeneration
Synthetic Macrocycles in Small-Molecule Drug Discovery
Glossary of Terms Used in Medicinal Chemistry Part II (IUPAC Recommendations 2011)
Case History: XalkoriTM (Crizotinib), a Potent and Selective Dual Inhibitor of MET and ALK for Cancer Treatment
Case History: Vemurafenib, a Potent, Selective, and First-in-Class Inhibitor of Mutant BRAF for the Treatment of Metastatic Melanoma
New Chemical Entities Entering Phase III Trials in 2012 28. To Market, to Market-2012